MicroRNA-608 sensitizes non-small cell lung cancer cells to cisplatin by targeting TEAD2

Cisplatin has been widely used as a conventional treatment for patients with non-small cell lung cancer (NSCLC). However, primary and acquired cisplatin resistances are frequently developed during the treatment of patients with NSCLC, leading to an increased mortality rate. Accumulating evidence dem...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yanli, Li, Fengcai, Ma, Dandan, Gao, Yuhua, Li, Runpu, Gao, Yingjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755186/
https://www.ncbi.nlm.nih.gov/pubmed/31485614
http://dx.doi.org/10.3892/mmr.2019.10616

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755186/
https://www.ncbi.nlm.nih.gov/pubmed/31485614
http://dx.doi.org/10.3892/mmr.2019.10616

Ejemplares similares